Previous Close | 223.37 |
Open | 225.33 |
Bid | 231.85 x 1000 |
Ask | 236.00 x 3200 |
Day's Range | 224.40 - 233.88 |
52 Week Range | 117.58 - 233.88 |
Volume | |
Avg. Volume | 997,419 |
Market Cap | 27.846B |
Beta (5Y Monthly) | 0.74 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -7.49 |
Earnings Date | Oct 26, 2022 - Oct 31, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 228.45 |
Subscribe to Yahoo Finance Plus to view Fair Value for ALNY
Analysts said the results were strong enough that the drug could be the go-to treatment once it is approved.
Alnylam stock cooled Friday as one expert argued the company will have to run a second study of its cardiomyopathy drug to gain traction.
A gene-editing treatment from Intellia led to elevated liver enzymes in one patient with polyneuropathy, prodding NTLA stock to topple.